Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $33.8 million.

  • Inhibrx Biosciences' Operating Expenses fell 2774.75% to $33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.4 million, marking a year-over-year decrease of 5816.63%. This contributed to the annual value of $331.6 million for FY2024, which is 5005.27% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Operating Expenses of $33.8 million as of Q3 2025, which was down 2774.75% from $28.7 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Operating Expenses ranged from a high of $161.0 million in Q2 2024 and a low of $28.7 million during Q2 2025
  • Its 3-year average for Operating Expenses is $61.4 million, with a median of $46.4 million in 2023.
  • Per our database at Business Quant, Inhibrx Biosciences' Operating Expenses skyrocketed by 28917.55% in 2024 and then crashed by 8218.05% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' Operating Expenses (Quarter) stood at $89.9 million in 2023, then tumbled by 44.37% to $50.0 million in 2024, then plummeted by 32.41% to $33.8 million in 2025.
  • Its Operating Expenses was $33.8 million in Q3 2025, compared to $28.7 million in Q2 2025 and $42.9 million in Q1 2025.